This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pick, E. Articles by Kluger, H. M. Search for Related Content PubMed PubMed Citation Articles by Pick, E. Articles by Kluger, H. M.

High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer

Departments of ¹ Medicine and ² Pathology, Yale University School of Medicine, New Haven, Connecticut and ³ Department of Cell Biology, New York University, New York, New York

Requests for reprints: Harriet M. Kluger, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520. Phone: 203-785-6221; Fax: 203-785-3788; E-mail: Harriet.Kluger{at}yale.edu.

The heat shock protein HSP90 chaperones proteins implicated in breast cancer progression, including Her2/neu. HSP90-targeting agents are in clinical trials for breast cancer. HSP90 expression is high in breast cancer cell lines, yet no large studies have been conducted on expression in human tumors and the association with clinical/pathologic variables. Tissue microarrays containing 10 cell lines and primary specimens from 655 patients with 10-year follow-up were assessed using our automated quantitative analysis (AQUA) method; we used cytokeratin to define pixels as breast cancer (tumor mask) within the array spot and measured HSP90 expression within the mask using Cy5-conjugated antibodies. We similarly assessed estrogen receptor, progesterone receptor, and Her2/neu expression. HSP90 expression was more variable in human tumors than in cell lines (P < 0.0001). High HSP90 expression was associated with decreased survival (P = 0.0024). On multivariable analysis, high HSP90 expression remained an independent prognostic marker. High HSP90 expression was associated with high Her2/neu and estrogen receptor, large tumors, high nuclear grade, and lymph node involvement. Although HSP90 levels were high in all our cell lines, expression in tumors was more variable. High HSP90 expression in primary breast cancer defines a population of patients with decreased survival. Evaluation of HSP90 expression in early-stage breast cancer may identify a subset of patients requiring more aggressive or pathway-targeted treatment. Prospective studies are needed to confirm the prognostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors. [Cancer Res 2007;67(7):2932–7]

This article has been cited by other articles:

				C. C. Leow, J. Chesebrough, K. T. Coffman, C. A. Fazenbaker, J. Gooya, D. Weng, S. Coats, D. Jackson, B. Jallal, and Y. Chang Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib Mol. Cancer Ther., August 1, 2009; 8(8): 2131 - 2141. [Abstract] [Full Text] [PDF]

				C. M. Gould, N. Kannan, S. S. Taylor, and A. C. Newton The Chaperones Hsp90 and Cdc37 Mediate the Maturation and Stabilization of Protein Kinase C through a Conserved PXXP Motif in the C-terminal Tail J. Biol. Chem., February 20, 2009; 284(8): 4921 - 4935. [Abstract] [Full Text] [PDF]

				U. Banerji Heat Shock Protein 90 as a Drug Target: Some Like It Hot Clin. Cancer Res., January 1, 2009; 15(1): 9 - 14. [Abstract] [Full Text] [PDF]

				M. Zajac, M. V. Moneo, A. Carnero, J. Benitez, and B. Martinez-Delgado Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines Mol. Cancer Ther., August 1, 2008; 7(8): 2358 - 2366. [Abstract] [Full Text] [PDF]

				Y. Yang, R. Rao, J. Shen, Y. Tang, W. Fiskus, J. Nechtman, P. Atadja, and K. Bhalla Role of Acetylation and Extracellular Location of Heat Shock Protein 90{alpha} in Tumor Cell Invasion Cancer Res., June 15, 2008; 68(12): 4833 - 4842. [Abstract] [Full Text] [PDF]

				S. A. Eccles, A. Massey, F. I. Raynaud, S. Y. Sharp, G. Box, M. Valenti, L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis Cancer Res., April 15, 2008; 68(8): 2850 - 2860. [Abstract] [Full Text] [PDF]

				M. M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, R. L. Camp, D. L. Rimm, and H. M. Kluger HSP90 as a marker of progression in melanoma Ann. Onc., March 1, 2008; 19(3): 590 - 594. [Abstract] [Full Text] [PDF]

				D. Faingold, J.-C. Marshall, E. Antecka, S. Di Cesare, A. N. Odashiro, S. Bakalian, B. F. Fernandes, and M. N. Burnier Jr. Immune Expression and Inhibition of Heat Shock Protein 90 in Uveal Melanoma Clin. Cancer Res., February 1, 2008; 14(3): 847 - 855. [Abstract] [Full Text] [PDF]

				K. Sidera, M. Gaitanou, D. Stellas, R. Matsas, and E. Patsavoudi A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2 J. Biol. Chem., January 25, 2008; 283(4): 2031 - 2041. [Abstract] [Full Text] [PDF]